A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

NCT07650916 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

564

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: CAB ULA
DRUG: RPV ULA
DRUG: CAB LA
DRUG: RPV LA

Sponsor

ViiV Healthcare